Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Pancreatic Cancer, Serous Ovarian Cancer
Interventions: VCN-01, huCART-meso Cells; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes, Hypoglycemia, Aging
Interventions: Not listed
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 65 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus
Interventions: IDegLira, Insulin Degludec (U-100), Insulin Aspart; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Thyroid Cancer
Interventions: Radioactive Iodine 124; Radiation
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Type 2 Diabetes
Interventions: Routine Care + Glycemic Excursion Minimization (RC+GEM), Routine Care (RC); Behavioral · Other
Lead sponsor: Chiara Fabris, PhD; Other
Eligibility: 30 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Aurora, Colorado • Charlottesville, Virginia

Conditions: Type 1 Diabetes
Interventions: Not listed
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 20 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes, Wound Infection, Healthy Volunteers
Interventions: Ceftolozane/tazobactam, Microdialysis Catheter Insertion; Drug · Procedure
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Interventions: Palazestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane; Drug
Lead sponsor: Olema Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 47
States / cities: Tucson, Arizona • Fountain Valley, California • Glendale, California + 39 more

Conditions: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Tumor Virus Infections
Interventions: CC-486, Carboplatin, ABI-007; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 7
States / cities: Scottsdale, Arizona • San Francisco, California • Indianapolis, Indiana + 4 more

Conditions: Type 2 Diabetes, Obesity
Interventions: Meal Replacement, Standard Care; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes, HIV/AIDS, FOOD SECURITY
Interventions: Food assistance; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Prompt Sham, Prompt aflibercept, Deferred laser, Deferred aflibercept; Procedure · Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 81
States / cities: Phoenix, Arizona • Tucson, Arizona • Huntington Beach, California + 68 more

Conditions: Down Syndrome (Trisomy 21), Edwards Syndrome (Trisomy 18), Patau Syndrome (Trisomy 13), Turner Syndrome
Interventions: Not listed
Lead sponsor: Sequenom, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 7
States / cities: La Jolla, California • San Diego, California • San Jose, California + 4 more

Conditions: Metastatic Pancreatic Cancer
Interventions: Ascorbic Acid, nab paclitaxel, Cisplatin, Gemcitabine; Drug
Lead sponsor: Piedmont Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Atlanta, Georgia • Fayetteville, Georgia • Newnan, Georgia

Conditions: Oncologic Complications, Quality of Life, Nutrition Poor, Head and Neck Cancer, Lung Cancer, Pancreatic Cancer
Interventions: Dexamethasone, Dronabinol, Mirtazapine, Nutrition Intervention; Drug · Behavioral
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Postmenopausal Symptoms, Obesity, Prediabetic State
Interventions: Resistance Exercise, Endurance Exercise; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 50 Years to 75 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Pancreatic Cancer
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences LLC; Industry
Eligibility: Male only
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide, sitagliptin, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes Mellitus, Heart Failure
Interventions: HF DM self care, Usual Care; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Solid Tumor, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung
Interventions: ATI-1123 (active drug = docetaxel); Drug
Lead sponsor: Azaya Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Dallas, Texas • San Antonio, Texas

Conditions: Epithelial Ovarian Cancer
Interventions: Cvac, Placebo; Biological
Lead sponsor: Prima BioMed Ltd; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 6
States / cities: Los Angeles, California • Boynton Beach, Florida • Sarasota, Florida + 3 more

Conditions: Psychosocial Adjustment
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 10 Months to 4 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Ketoacidosis
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 6 Years to 25 Years
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer

Continuous Glucose Monitoring (CGM) in Long Term Care (LTC) Facilities

IDegLira HIGH Trial

Comparison of Iodine-124 (I-124) and Iodine-131 (I-131) Radiopharmacokinetics in Patients Prepared With Recombinant Human TSH Injection (rhTSH)

Treating Early Type 2 Diabetes by Reducing Postprandial Glucose Excursions: A Paradigm Shift in Lifestyle Modification

Multivariable Artificial Pancreas: Detecting and Mitigating Unannounced Physical Activity and Acute Psychological Stress

Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

A Trial of Meal Replacement at a Community Diabetes Clinic Serving a Low Socioeconomic Hispanic Population

Food Assistance, Diabetes, and HIV

Anti-VEGF Treatment for Prevention of PDR/DME

Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Nutrition and Pharmacological Algorithm for Oncology Patients Study

Exercise Training and Fat Metabolism in Postmenopausal Women

Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer

Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione

Cost Effectiveness and Quality of Life in Heart Failure Patients With Diabetes

Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment

Endocrine and Psychological Evaluation of Adopted Children

Diabetic Ketoacidosis: Brain Morphology and Cognition

Glycemic Monitoring in Cystic Fibrosis